{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:16:57Z","timestamp":1792225017447,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lymphatic metastasis is the dominant route of initial spread for most solid tumors. For many such malignancies, including melanomas, surgical treatment previously included removal of all potentially draining regional lymph nodes (elective node dissection). The advent of lymphatic mapping and sentinel lymph node (SLN) biopsy allowed accurate pathologic assessment of the metastatic status of regional nodes and spared patients full dissection if their SLN was clear. In melanoma, recent clinical research has demonstrated that complete lymph node dissection is not clinically beneficial, even for patients with sentinel node metastases and that patients with high-risk primary melanomas benefit from adjuvant systemic immunotherapy, even without nodal disease. These two changes in the standard of care have led to some interest in abandoning surgical nodal staging via the sentinel lymph node biopsy procedure. However, this appears to be premature and potentially detrimental to optimal patient management. The ongoing value of sentinel node biopsy stems from its ability to provide critically important prognostic information as well as durable regional nodal disease control for most patients with nodal metastases, even in the absence of complete dissection of the basin. It also provides an opportunity to identify novel prognostic and predictive immunologic and molecular biomarkers. While it is certainly possible that additional changes in melanoma therapy will make sentinel lymph node biopsy obsolete in the future, at present it remains a minimally invasive, low morbidity means of improving both staging and outcomes.<\/jats:p>","DOI":"10.1007\/s10585-023-10254-2","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T07:02:06Z","timestamp":1704178926000},"page":"369-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sentinel lymph nodes in melanoma: necessary as ever for optimal treatment"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1752-7282","authenticated-orcid":false,"given":"Mark B.","family":"Faries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"10254_CR1","doi-asserted-by":"crossref","unstructured":"Snow HM Melanotic cancerous Disease. Lancet 140:869\u2013922, 1892","DOI":"10.1016\/S0140-6736(01)88089-2"},{"key":"10254_CR2","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","volume":"17","author":"MB Faries","year":"2010","unstructured":"Faries MB, Thompson JF, Cochran A et al (2010) The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in Melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 17:3324\u20133329","journal-title":"Ann Surg Oncol"},{"key":"10254_CR3","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z","volume":"41","author":"FH Sim","year":"1978","unstructured":"Sim FH, Taylor WF, Ivins JC et al (1978) A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant Melanoma. Preliminary results. Cancer 41:948\u2013956","journal-title":"Cancer"},{"key":"10254_CR4","doi-asserted-by":"crossref","unstructured":"Balch CM, Soong SJ, Bartolucci AA et al (1996) : Efficacy of an elective regional lymph node dissection of 1 to 4\u00a0mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255\u2009\u2013\u200963; discussion 263-6,","DOI":"10.1097\/00000658-199609000-00002"},{"key":"10254_CR5","unstructured":"Balch CM, Cascinelli N, Sim FH (2003) Elective lymph node dissection: results of prospective Randomized Surgical trials. In: Balch CM, Houghton AN, Sober AJ et al (eds) Cutaneous Melanoma. Saint Louis, MO, Quality Medical Publishing, pp 379\u2013395"},{"key":"10254_CR6","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2","volume":"49","author":"U Veronesi","year":"1982","unstructured":"Veronesi U, Adamus J, Bandiera DC et al (1982) Delayed regional lymph node dissection in stage I Melanoma of the skin of the lower extremities. Cancer 49:2420\u20132430","journal-title":"Cancer"},{"key":"10254_CR7","first-page":"793","volume":"351","author":"N Cascinelli","year":"1998","unstructured":"Cascinelli N, Morabito A, Santinami M et al (1998) Immediate or delayed dissection of regional nodes in patients with Melanoma of the trunk: a randomised trial. WHO Melanoma Programme Lancet 351:793\u2013796","journal-title":"WHO Melanoma Programme Lancet"},{"key":"10254_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"D Morton","year":"1992","unstructured":"Morton D, Wen D, Wong J et al (1992) Technical details of intraoperative lymphatic mapping for early stage Melanoma. Arch Surg 127:392\u2013399","journal-title":"Arch Surg"},{"key":"10254_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","volume":"242","author":"D Morton","year":"2005","unstructured":"Morton D, Cochran A, Thompson J et al (2005) Sentinel node biopsy for early-stage Melanoma: accuracy and morbidity in MSLT-1, an interanational multicenter trial. Ann Surg 242:302\u2013311","journal-title":"Ann Surg"},{"key":"10254_CR10","doi-asserted-by":"crossref","unstructured":"Morton DL, Thompson JF, Essner R et al (1999) : Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage Melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230:453\u2009\u2013\u200963; discussion 463-5,","DOI":"10.1097\/00000658-199910000-00001"},{"issue":"Suppl 5","key":"10254_CR11","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N et al (2015) Cutaneous Melanoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v126\u2013v132","journal-title":"Ann Oncol"},{"key":"10254_CR12","doi-asserted-by":"crossref","unstructured":"Coit DG, Andtbacka R, Anker CJ et al Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:395\u2013407","DOI":"10.6004\/jnccn.2013.0055"},{"key":"10254_CR13","doi-asserted-by":"crossref","unstructured":"Wong SL, Balch CM, Hurley P et al Sentinel lymph node biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30:2912\u20132918","DOI":"10.1200\/JCO.2011.40.3519"},{"key":"10254_CR14","first-page":"73","volume-title":"Clinical practice guidelines for the management of Melanoma in Australia and New Zealand","author":"AustralianCancerNetwork","year":"2008","unstructured":"AustralianCancerNetwork (2008) Clinical practice guidelines for the management of Melanoma in Australia and New Zealand. New Zealand Guidelines Group, Wellington, New Zealand, pp 73\u201375"},{"key":"10254_CR15","unstructured":"Kirkwood J, Ibrahim J, Sondak V (1998) : Role of high-dose interferon in high risk melanoma: preliminary results of the E1690\/S9111\/C9190 US intergroup post-operative adjuvant trial of high and low dose interferon alpha 2b in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. Symposium on Advances in Biology and Treatment of Cutaneous Melanoma,"},{"key":"10254_CR16","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2018) : Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med,","DOI":"10.1056\/NEJMoa1802357"},{"key":"10254_CR17","doi-asserted-by":"crossref","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) : Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med,","DOI":"10.1056\/NEJMoa1709030"},{"key":"10254_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive Melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757\u2013767","journal-title":"Lancet Oncol"},{"key":"10254_CR19","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ et al (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211\u20132222","journal-title":"N Engl J Med"},{"key":"10254_CR20","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P et al (2022) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC Melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399:1718\u20131729","journal-title":"Lancet"},{"key":"10254_CR21","doi-asserted-by":"crossref","unstructured":"Long GV, Del Vecchio M, Weber J, Hoeller C, Grob J-J, ., Mohr P, ., Grabbe S, Dutriaux C, Chiarion-Sileni V, ., Mackiewicz J, ., Rutkowski P, ., Arenberger P, ., Qu\u00e9reux G, ., Meniawy T, Ascierto PA, ., Durani P, ., Lobo M, Campigotto F, Gastman B, Kirkwood JM Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB\/C melanoma (CheckMate 76K). WCH23 Dermatology Conference. Hawaii, 2023","DOI":"10.25251\/skin.7.supp.163"},{"key":"10254_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"10254_CR23","doi-asserted-by":"crossref","unstructured":"El Sharouni MA, Stodell MD, Ahmed T et al (2020) : Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol,","DOI":"10.1016\/j.annonc.2020.11.015"},{"key":"10254_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMoa030681","volume":"350","author":"JM Thomas","year":"2004","unstructured":"Thomas JM, Newton-Bishop J, A\u2019Hern R et al (2004) Excision margins in high-risk malignant Melanoma. N Engl J Med 350:757\u2013766","journal-title":"N Engl J Med"},{"key":"10254_CR25","first-page":"835","volume":"157","author":"G Study","year":"2022","unstructured":"Multicenter Selective Lymphadenectomy Trials, Study G, Crystal JS, Thompson JF et al (2022) Therapeutic Value of Sentinel Lymph Node Biopsy in patients with Melanoma: a Randomized Clinical Trial. JAMA Surg 157:835\u2013842","journal-title":"JAMA Surg"},{"key":"10254_CR26","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1245\/s10434-009-0420-x","volume":"16","author":"WC Conway","year":"2009","unstructured":"Conway WC, Faries MB, Nicholl MB et al (2009) Age-related lymphatic dysfunction in Melanoma patients. Ann Surg Oncol 16:1548\u20131552","journal-title":"Ann Surg Oncol"},{"key":"10254_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-18-0168","volume":"9","author":"BL Ecker","year":"2019","unstructured":"Ecker BL, Kaur A, Douglass SM et al (2019) Age-related changes in HAPLN1 increase lymphatic permeability and affect routes of Melanoma Metastasis. Cancer Discov 9:82\u201395","journal-title":"Cancer Discov"},{"key":"10254_CR28","unstructured":"Swetter SM, Johnson D, Thompson JA et al (2023) : Melanoma: Cutaneous,"},{"key":"10254_CR29","doi-asserted-by":"crossref","unstructured":"Lo SN, Ma J, Scolyer RA et al (2020) An improved risk-prediction calculator for sentinel node positivity in Melanoma patients: the MIA Nomogram. J Clin Oncol Epub ahead of print","DOI":"10.1200\/JCO.19.02362"},{"key":"10254_CR30","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1245\/s10434-020-09563-7","volume":"28","author":"AW Kangas-Dick","year":"2021","unstructured":"Kangas-Dick AW, Greenbaum A, Gall V et al (2021) Evaluation of a gene expression profiling assay in primary cutaneous Melanoma. Ann Surg Oncol 28:4582\u20134589","journal-title":"Ann Surg Oncol"},{"key":"10254_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y et al (2023) Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in Advanced Melanoma. N Engl J Med 388:813\u2013823","journal-title":"N Engl J Med"},{"key":"10254_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L et al (2022) Treatment landscape of triple-negative Breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol 19:91\u2013113","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10254-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10254-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:13:44Z","timestamp":1725462824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10254-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10254"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10254-2","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MBF has received honoraria for participation in advisory boards for: Merck, Bristol-Myers Squibb, Regeneron, and Instil Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}